PMID- 31104007
OWN - NLM
STAT- MEDLINE
DCOM- 20191206
LR  - 20191217
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 25
IP  - 2
DP  - 2019
TI  - Positive BCL2L12 expression predicts favorable prognosis in patients with 
      laryngeal squamous cell carcinoma.
PG  - 141-149
LID - 10.3233/CBM-181772 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) constitutes the third most 
      frequent head and neck cancer. Several tissue biomarkers have been studied for 
      their prognostic significance in LSCC. OBJECTIVE: To investigate the prognostic 
      significance of BCL2L12, a new member of the BCL2 family, in primary LSCC along 
      with well-examined biomarkers such as BCL2 and BAX. METHODS: Cancerous tissue 
      specimens of patients with primary LSCC were collected during 2005 and 2012 as 
      pretreatment tissue biopsy. The specimens were immunohistochemically evaluated 
      for the protein expression of BCL2L12, BCL2 and BAX. Kaplan-Meier survival curves 
      and Cox proportional hazard regression models were performed to evaluate 
      prognosis. RESULTS: In the study cohort of 78 patients with primary LSCC, 
      Kaplan-Meier survival curves demonstrated that advanced-stage LSCC patients with 
      BCL2L12-positive tumors had significantly higher OS time in comparison with 
      advanced-stage LSCC patients with BCL2L12-negative tumors (p= 0.014). Also, 
      advanced-stage LSCC patients with BCL2L12-positive tumors had significantly lower 
      risk of death from LSCC compared to advanced-stage LSCC patients with 
      BCL2L12-negative tumors (HR = 0.228, 95%CI = 0.063-0.833, p= 0.025). CONCLUSIONS: 
      BCL2L12 protein expression could be used as a favorable prognostic tissue 
      biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and 
      BAX did not correlate with prognosis in patients with primary LSCC.
FAU - Giotakis, Aris I
AU  - Giotakis AI
AD  - First Department of Otorhinolaryngology, Hippocration Hospital, Medical 
      University of Athens, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Lazaris, Andreas C
AU  - Lazaris AC
AD  - Department of Pathology, Medical University of Athens, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Kataki, Agapi
AU  - Kataki A
AD  - Laboratory of Surgical Research, 1st Department of Propaedeutic Surgery, 
      Hippocration Hospital, Medical University of Athens, National and Kapodistrian 
      University of Athens, Athens, Greece.
FAU - Kontos, Christos K
AU  - Kontos CK
AD  - Department of Biochemistry and Molecular Biology, University of Athens, Athens, 
      Greece.
FAU - Giotakis, Evangelos I
AU  - Giotakis EI
AD  - First Department of Otorhinolaryngology, Hippocration Hospital, Medical 
      University of Athens, National and Kapodistrian University of Athens, Athens, 
      Greece.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (BAX protein, human)
RN  - 0 (BCL2L12 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Muscle Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-2-Associated X Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor
MH  - Carcinoma, Squamous Cell/*genetics/*mortality/pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Muscle Proteins/*genetics/metabolism
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-2/*genetics/metabolism
MH  - bcl-2-Associated X Protein/genetics/metabolism
OTO - NOTNLM
OT  - BCL2L12
OT  - Laryngeal neoplasms
OT  - biomarkers
OT  - prognosis
OT  - survival
EDAT- 2019/05/20 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/05/20 06:00
PHST- 2019/05/20 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/05/20 06:00 [entrez]
AID - CBM181772 [pii]
AID - 10.3233/CBM-181772 [doi]
PST - ppublish
SO  - Cancer Biomark. 2019;25(2):141-149. doi: 10.3233/CBM-181772.